Videos

Men of African Ancestry Less Likely to Receive Genomic Profiling Early During Prostate Cancer Treatment

June 5th 2021

The data, according to one of the study’s authors, are critical in understanding the disparities in prostate cancer.

Disparities in Gastric Cancer

June 4th 2021

Yanghee Woo, M.D., comments on disparities in healthcare for select patients with gastric cancer and describes how these impact the diagnosis and treatment of the disease.

Gastric Cancer in Young Adults

June 4th 2021

City of Hope’s Yanghee Woo, M.D., highlights risk factors for gastric cancer and comments on the rise in cases in adults 40 years of age and younger.

November 2020 Pull Up A Seat: Cancer While Black

June 4th 2021

The Tigerlily Foundation and Guiding Researchers and Advocates for Scientific Partnerships (GRASP) November conversation focused on what it means to have “Cancer While Black: Moving Past the Medical Mistrust Impact."

Taking Control of Multiple Myeloma

June 2nd 2021

Donna and Dr Gasparetto close the discussion by highlighting the importance of physicians utilizing their patients, as well as patients being involved with their multiple myeloma treatment.

Donna’s Advice to Multiple Myeloma Patients

June 2nd 2021

Donna gives advice to other multiple myeloma patients about what she has learned from living with this disease and her various therapies.

Personalized Medicine in Thyroid Cancer

June 2nd 2021

Lori J. Wirth, MD, of Massachusetts General Hospital, comments on the role of molecular testing to guide treatment decisions in thyroid cancer and explains how personalized medicine differs from standard treatment approaches.

Molecular Testing for NSCLC: Historical Perspectives

June 2nd 2021

Benjamin Levy, MD, of Johns Hopkins Sidney Kimmel Cancer Center, describes how molecular testing in non–small cell lung cancer has advanced and impacted treatment.

2021 Ask the Bladder Cancer Experts

June 2nd 2021

Ask the Experts is a question and answer session with two of the leading bladder cancer experts in the United States, Kent Mouw, MD, PhD and Sarah P Psutka, MD, MSc.

October 2020 Pull Up A Seat: Cancer While Black

May 28th 2021

The Tigerlily Foundation and GRASP presents a conversation with Dr. Tisha M. Felder on what it means to have “Cancer While Black: How Trauma, Fear, Generational Pain & Mistrust Impact Breast Cancer.”

Educated Patient® Webinar: Empowering Patients to Understand Cancer Genetic Testing and Counseling

May 27th 2021

View the full CURE® Educated Patient® Webinar: Empowering Patients to Understand Cancer Genetic Testing and Counseling on demand.

Donna’s Switch to Selinexor and MM Clinical Trial Treatment

May 27th 2021

Cristina Gasparetto, MD, discusses Donna’s next line of therapy, selinexor, and how being part of a clinical trial impacted her multiple myeloma.

Multiple Myeloma and CAR T Cell Therapy

May 27th 2021

Donna’s multiple myeloma treatment changes with the help of Dr Cristina Gasparetto’s direct influence and CAR T cell therapy.

Carfilzomib for Multiple Myeloma and Donna’s Second Relapse

May 21st 2021

Cristina Gasparetto, MD, discusses Donna’s relationship with the drug carfilzomib for multiple myeloma therapy, as well as her second relapse.

Multiple Myeloma First- and Second-Line Therapies for Donna

May 21st 2021

Donna and Dr Gasparetto converse about the many first- and second-line therapies for multiple myeloma.

Multiple Myeloma Maintenance and Donna’s First Relapse

May 21st 2021

Cristina Gasparetto, MD, details typical multiple myeloma maintenance in comparison with Donna’s therapies, and Donna tells us about her first relapse with multiple myeloma.

Donna’s Multiple Myeloma Transplants and Chemotherapy

May 21st 2021

We learn more about Donna’s 2 transplants, her chemotherapy, and how they impacted her quality of life.

Donna’s Road to Multiple Myeloma Diagnosis and Transplants

May 21st 2021

Donna discusses her multiple myeloma diagnosis and the start of her treatment, while Dr Gasparetto educates on the importance of transplants.

Multiple Myeloma and Donna’s Symptoms: An Overview

May 21st 2021

Cristina Gasparetto, MD, gives a brief overview of the multiple myeloma disease state and introduces us to Donna, one of her patients diagnosed with multiple myeloma.

Why It’s Important to Be a Well-Educated, Proactive Patient

May 19th 2021

Patients with cancer can advocate for themselves by researching their illnesses and treatments before an appointment, so they’re able to ask better questions, says an expert from the HealthTree Foundation & Myeloma Crowd.

Treatment Considerations for TIL Therapy in NSCLC

May 18th 2021

An expert thoracic oncologist, Adam J. Schoenfeld, MD, highlights key factors that patients and providers should take into account when considering cell therapy in non–small cell lung cancer.

Clinical Trials of TIL Therapy in NSCLC

May 18th 2021

A key opinion leader in the management of lung cancer offers insight into ongoing clinical trials of tumor-infiltrating lymphocyte (TIL) therapy in non–small cell lung cancer.

Immunotherapy Could 'Provide A Whole New Realm' For Patients with Myeloma

May 14th 2021

New advances in research around immunotherapies for patients with myeloma are on the horizon, according to an expert from the HealthTree Foundation & Myeloma Crowd.

How to Conduct Self-Exams for Head and Neck Cancer

May 12th 2021

Discussing Survivorship in Head and Neck Cancer

May 12th 2021

Emerging Treatments for Head and Neck Cancer

May 12th 2021

Addressing HPV-Related Head and Neck Cancer

May 12th 2021

Understanding the Basics of Head and Neck Cancer

May 12th 2021

The Potential Role of TIL Therapy in NSCLC

May 11th 2021

Adam J. Schoenfeld, MD, considers the benefits and limitations of tumor-infiltrating lymphocyte (TIL) therapy and discusses its potential impact on the treatment landscape in non–small cell lung cancer.

An Overview of TIL Therapy

May 11th 2021

An expert in the management of non–small cell lung cancer defines tumor-infiltrating lymphocyte (TIL) therapy by discussing its mechanism of action and reviewing its impact in other disease states, such as myeloma.